Objective:

To approve olezarsen (Tryngolza) for reducing triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

Approach:

• Clinical Trials: Two randomized, double-blind, placebo-controlled trials with 1,061 adults were conducted to evaluate the efficacy of olezarsen.

Key Findings:

• Mean baseline triglyceride levels were 1,116 mg/dL.
• In one trial, triglyceride levels decreased by 63% and 72% with 50-mg and 80-mg doses, respectively.
• In the second trial, reductions were 49% and 55% with the 50-mg and 80-mg doses, respectively.
• A pooled analysis indicated a lower incidence of acute pancreatitis in patients receiving olezarsen compared to placebo.

Interpretation:

The FDA recommends liver enzyme testing before treatment initiation and ongoing monitoring due to potential adverse reactions.

Limitations:

• The trials primarily focused on short-term efficacy and safety.
• Long-term effects and safety profile of olezarsen remain to be fully established.

Conclusion:

Olezarsen received Priority Review and Breakthrough Therapy designations for its indication.

Sources:

• US Food and Drug Administration